Top

Supportive Care in Cancer

Published in:

01-01-2016 | Letter to the editor

Towards a better understanding of the relationship between side effects of analgesia and quality of life in patients with multiple myeloma

Authors: Pasquale Niscola, Agostina Siniscalchi, Andrea Tendas, Paolo de Fabritiis, Tommaso Caravita, Fabio Efficace

Published in: Supportive Care in Cancer | Issue 1/2016

Excerpt

Dear Editor, …

Sloot S, Boland J, Snowden JA, Ezaydi Y, Foster A, Gethin A, Green T, Chopra L, Verhagen S, Vissers K, Engels Y, Ahmedzai SH (2015) Side effects of analgesia may significantly reduce quality of life in symptomatic multiple myeloma: a cross-sectional prevalence study. Support Care Cancer 23(3):671–678PubMedCentralCrossRefPubMed

Niscola P, Scaramucci L, Romani C, Giovannini M, Tendas A, Brunetti G, Cartoni C, Palumbo R, Vischini G, Siniscalchi A, de Fabritiis P, Caravita T (2010) Pain management in multiple myeloma. Expert Rev Anticancer Ther 10(3):415–425CrossRefPubMed

Poulos AR, Gertz MA, Pankratz VS, Post-White J (2001) Pain, mood disturbance, and quality of life in patients with multiple myeloma. Oncol Nurs Forum 28(7):1163–1171, 8 PubMed

Niscola P, Tendas A, Giovannini M, Scaramucci L, Cupelli L, Ferrannini M, Brunetti GA, Bondanini F, Palumbo R, Perrotti A, Romani C, Cartoni C, Efficace F, de Fabritiis P (2012) Pain management in hematological patients with major organ dysfunctions and comorbid illnesses. Cardiovasc Hematol Agents Med Chem 10(2):135–147CrossRefPubMed

Jordan K, Proskorovsky I, Lewis P, Ishak J, Payne K, Lordan N, Kyriakou C, Williams CD, Peters S, Davies FE (2014) Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer 22(2):417–426PubMedCentralCrossRefPubMed

Husson O, Mols F, van de Poll-Franse LV (2011) The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: a systematic review. Annals of Oncology 22(4):761–772PubMedCentralCrossRefPubMed

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes J, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376CrossRefPubMed

Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM (2011) Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 29(1):89–96CrossRefPubMed

Cocks K, King MT, Velikova G, de Castro G Jr, Martyn St-James M, Fayers PM, Brown JM (2012) Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer 48(11):1713–1721CrossRefPubMed

10.

Litwin MS, McGuigan KA (1999) Accuracy of recall in health-related quality-of-life assessment among men treated for prostate cancer. J Clin Oncol 17(9):2882–2888PubMed

Title: Towards a better understanding of the relationship between side effects of analgesia and quality of life in patients with multiple myeloma
Authors: Pasquale Niscola
Agostina Siniscalchi
Andrea Tendas
Paolo de Fabritiis
Tommaso Caravita
Fabio Efficace
Publication date: 01-01-2016
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 1/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-015-2868-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2016

Relationship between palliative care consultation service and end-of-life outcomes

In-service documentation tools and statements on palliative sedation in Germany—do they meet the EAPC framework recommendations? A qualitative document analysis

Addressing psychosocial needs of partners of breast cancer patients: a pilot program using social workers to improve communication and psychosocial support

Identifying trajectory clusters in breast cancer survivors’ supportive care needs, psychosocial difficulties, and resources from the completion of primary treatment to 8 months later

The need and availability of dental services for terminally ill cancer patients: a nationwide survey in Japan

Psychosocial factors associated with adherence for self-management behaviors in women with breast cancer-related lymphedema

Keynote webinar | Spotlight on antibody–drug conjugates in cancer